Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rocket Pharmaceuticals Inc

RCKT ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: HOLD

Last Close

$3.78

▲ +7.08%

Market Cap $414.95M · Vol 357.35K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$414.95M

Small Cap

Div Yield

N/A

EPS Growth

+92.49%

YoY

RSI (14)

59.46

Momentum

Beta

0.50

vs Market

52W High

$5.45

30.64% below

52W Low

$2.53

49.41% above

Volume

357.35K

Avg 381.26K

P/B

1.37

Price-to-book

ROE

-60.27%

Return on equity

Free Float

96.77%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Rocket Pharmaceuticals Inc (RCKT) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RCKT pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+13.17%

+18.50%

+27.70%

-12.70%

YTD

+7.69%

+6.78%

-76.14%

-87.77%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-223,123,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-60.27%
ROA · ROIC	-52.00% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.37
P/FCF	N/A
EPS Growth	+92.49%
Outstanding Shares	109.77M

Technical Indicators

50-Day SMA	$3.47
200-Day SMA	$3.55
RSI (14)	59.46
Beta	0.50
52-Week High	$5.45
52-Week Low	$2.53

Volume Today	357.35K
Avg Daily Volume (30D)	381.26K
Relative Volume	0.94x
Volatility (10D)	66.42
Volatility (30D)	56.78
Free Float	96.77%

Analyst Consensus

HOLD

Current Price $3.78

Mean Target $8.63

52W Low$2.53 52W High$5.45

Current

Target

$2.53 $5.45

Current Analyst target

+128.17% upside potential · 14 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001T92156

ISINUS77313F1066

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +3.29% ARGX.BR argenx SE +1.74% ARGX argenx SE +0.83% 2269.HK WuXi Biologics (Cayman) Inc +7.41% INSM Insmed Inc -0.07%

Company Profile

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.